List of Ozurdex drug patents
Ozurdex is owned by Allergan.
Ozurdex contains Dexamethasone.
Ozurdex has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Ozurdex are:
- US10702539
- US8506987
- US8034370
- US8034366
- US9192511
- US10076526
Ozurdex was authorised for market use on 17 June, 2009.
Ozurdex is available in implant;intravitreal dosage forms.
Ozurdex can be used as treatment of macular edema; treatment of uveitis, delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex, treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye.
The generics of Ozurdex are possible to be released after 01 November, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(21 days ago) | |
| US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(21 days ago) | |
| US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(21 days ago) | |
| US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(21 days ago) | |
| US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(21 days ago) | |
| US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(21 days ago) | |
| US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(8 months from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; Treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex
Dosage: IMPLANT;INTRAVITREAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic